HBM BioCapital II LP 4
4 · Allena Pharmaceuticals, Inc. · Filed Nov 8, 2017
Insider Transaction Report
Form 4
HBM BioCapital II LP
10% Owner
Transactions
- Conversion
Common Stock
2017-11-06+1,426,061→ 1,426,061 total - Purchase
Common Stock
2017-11-06$14.00/sh+71,428$999,992→ 1,638,330 total - Conversion
Series C Preferred Stock
2017-11-06−587,872→ 0 total→ Common Stock (140,841 underlying) - Conversion
Common Stock
2017-11-06+140,841→ 1,566,902 total - Conversion
Series B Preferred Stock
2017-11-06−5,952,380→ 0 total→ Common Stock (1,426,061 underlying)
Footnotes (3)
- [F1]Issued upon conversion of Series Series B Preferred Stock upon closing of Issuer's initial public offering.
- [F2]Issued upon conversion of Series Series C Preferred Stock upon closing of Issuer's initial public offering.
- [F3]Each share of the Issuer's Series B and Series C Preferred Stock automatically converted into one share of the Issuer's Common Stock on a 4.174-to-1 basis upon the closing of the Issuer's initial public offering and has no expiration date.